# Conventional Androgen Deprivation Therapy (ADT) With or Without Abiraterone Acetate + Prednisone and Apalutamide Following a Detectable PSA After Radiation and ADT

> **NCT03777982** · PHASE3 · TERMINATED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 12 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Prednisone
- **DRUG:** Apalutamide
- **DRUG:** Abiraterone Acetate
- **DRUG:** LHRH Agonist or Antagonist

## Key facts

- **NCT ID:** NCT03777982
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-04-20
- **Primary completion:** 2024-02-13
- **Final completion:** 2024-02-13
- **Target enrollment:** 12 (ACTUAL)
- **Why stopped:** PI is terminating the study due to slow/low accrual
- **Last updated:** 2024-09-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03777982

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03777982, "Conventional Androgen Deprivation Therapy (ADT) With or Without Abiraterone Acetate + Prednisone and Apalutamide Following a Detectable PSA After Radiation and ADT". Retrieved via MORVS 2026-10-12 from https://api.morvs.ai/clinical/NCT03777982. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*